Why these investments are being compared
Both compete for incremental SGX growth-compounder capital and both combine net cash with international expansion. Food Empire compounds through brands, distribution and new manufacturing capacity. UltraGreen compounds through procedure-driven ICG vial use, regulatory approvals, pricing and geographic adoption. Their sectors differ, so the comparison focuses on risk-adjusted capital allocation rather than operating similarity.
Side-by-side decision dashboard
| Dimension | Food Empire | UltraGreen.ai | Current leader |
|---|---|---|---|
| Dated price | S$2.35 | S$1.53 | — |
| Core earnings engine | Branded beverages, local distribution and factory utilisation | Regulated ICG vial volume, price and procedure penetration | Role-dependent |
| Revenue diversification | More than 60 countries; material Russia and Central Asia exposure | About 75% of FY2025 revenue from the Americas; one core pharmaceutical agent | Food Empire |
| Margin profile | About 20% normalized EBITDA margin | 85% gross margin; 62.8% adjusted EBITDA margin | UltraGreen |
| Balance sheet | Net cash | US$176.1m FY2025 net cash before 2026 deployment | Tie |
| Cash conversion | Exposed to capex and working-capital ramp | FY2025 operating cash flow lagged normalized NPAT | Food Empire, narrowly |
| Growth optionality | New coffee and snack capacity, premiumisation | New indications, markets, IC-Flow and quantification software | UltraGreen has greater upside range |
| Base expected return | 12%–16% | 10%–14% | Food Empire |
| Principal risk | Geopolitical, currency and capacity returns | Product, distributor and US pricing concentration; capital-allocation creep | Food Empire |
Earnings-engine comparison
Food Empire
Food Empire relies on repeat consumer demand, local pricing, commodity-cost management, distribution reach and utilisation of new factories. The growth path is more diversified by product and geography, but Russia and Central Asia remain an important profit concentration.
UltraGreen.ai
UltraGreen’s current economics are simpler than its branding suggests: recurring regulated ICG vials generate nearly all revenue and profit. Procedure adoption, vial volume and average selling price are the main variables. Imaging and software may strengthen the ecosystem, but UGDS revenue was immaterial and loss-making in FY2025.
Financial quality and capital allocation
Both have net cash. Food Empire is committing capital to plants whose utilisation and working capital can be observed. UltraGreen holds more cash relative to current operations, but has begun deploying it into software, biosensors and minority or convertible-note investments. UltraGreen’s balance sheet is stronger than its current needs; the open question is whether management converts that flexibility into per-share value.
Valuation and scenarios
At S$2.35, Food Empire’s normalized forward P/E remains in the mid-teens and the base return falls modestly to 12%–16%. At S$1.53, UltraGreen trades at roughly 20–21x normalized FY2025 earnings and an estimated 17–19x FY2026 earnings range. UltraGreen deserves a premium for margin and regulatory barriers, but the base case assigns little value to pre-commercial software.
| Scenario | Food Empire | UltraGreen.ai |
|---|---|---|
| Bear | Capacity returns disappoint, commodity or FX pressure persists and the concentration discount widens | Vial growth and pricing weaken, margins absorb platform spend and the multiple falls to 14–15x |
| Base | Normalized EPS compounds 10%–13% and new plants fill at acceptable returns | Vial volume grows 8%–11%, normalized EPS compounds about 10%–12% and the exit P/E is 18–20x |
| Bull | Premiumisation, diversification and high factory utilisation lift cash returns | International adoption remains mid-teens, margins hold and software produces credible paid revenue |
Portfolio fit
Food Empire adds consumer exposure but carries Russia, Central Asia and commodity sensitivity. UltraGreen adds healthcare exposure and lower direct macro sensitivity, but its concentrated product, customers and ownership require a smaller initial position. A portfolio already heavy in Food Empire’s geographies could reasonably choose a smaller UltraGreen position for diversification despite the lower modeled return.
Why UltraGreen could win
- 1H2026 confirms the upper half of revenue guidance with gross margin above 84%.
- Post-price-increase US volume remains durable while non-US adoption compounds faster.
- IC-Flow placements demonstrably increase recurring vial consumption.
- PerfusionWorks reaches approval and paying deployment without a large cost increase.
- Net cash is used for value-accretive buybacks or tightly related products rather than diffuse investments.
What would reverse the preference
UltraGreen moves ahead if the 12 August results validate double-digit underlying volume, strong cash conversion and disciplined platform spending, or if its relative price falls enough to create a clear high-teens expected return. Food Empire loses its lead if capacity additions absorb cash without adequate utilisation, or geopolitical and currency constraints materially impair cash generation.
Decision and action
Decision: Prefer Food Empire narrowly; selectively accumulate UltraGreen as a smaller healthcare-growth position.
Action: Direct more new SGX growth capital to Food Empire at S$2.35, while building UltraGreen only with position-size discipline at S$1.53.
Review trigger: UltraGreen 1H2026 results on 12 August, Food Empire 1H2026 results, or a 15% relative-price move.
Revision history
| Date | Preference | Relative-price context | What changed |
|---|---|---|---|
| 2 Aug 2026 | Food Empire, narrowly | Food Empire S$2.35; UltraGreen S$1.53, both 28 Jul closes | First current comparison established after refreshing UltraGreen’s filings, normalized earnings and current price; software is treated as optionality rather than a proven segment. |